BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8674057)

  • 21. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1995 May; 429():1-286. PubMed ID: 12616302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
    Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Jeglum KA; Santoli D
    Oncol Rep; 1999; 6(6):1181-8. PubMed ID: 10523677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
    Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
    Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
    Socinski MA
    Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.